Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 0.04
HLS's Cash to Debt is ranked lower than
51% of the 230 Companies
in the Global Medical Care industry.

( Industry Median: 0.28 vs. HLS: 0.04 )
HLS' s 10-Year Cash to Debt Range
Min: 0.02   Max: No Debt
Current: 0.04

Equity to Asset 0.14
HLS's Equity to Asset is ranked lower than
52% of the 231 Companies
in the Global Medical Care industry.

( Industry Median: 0.45 vs. HLS: 0.14 )
HLS' s 10-Year Equity to Asset Range
Min: -0.76   Max: 0.59
Current: 0.14

-0.76
0.59
Interest Coverage 4.80
HLS's Interest Coverage is ranked higher than
64% of the 160 Companies
in the Global Medical Care industry.

( Industry Median: 6.09 vs. HLS: 4.80 )
HLS' s 10-Year Interest Coverage Range
Min: 0.29   Max: 9999.99
Current: 4.8

0.29
9999.99
F-Score: 5
Z-Score: 1.06
M-Score: -2.78
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 21.46
HLS's Operating margin (%) is ranked higher than
95% of the 233 Companies
in the Global Medical Care industry.

( Industry Median: 9.44 vs. HLS: 21.46 )
HLS' s 10-Year Operating margin (%) Range
Min: -3.55   Max: 37.8
Current: 21.46

-3.55
37.8
Net-margin (%) 14.40
HLS's Net-margin (%) is ranked higher than
93% of the 233 Companies
in the Global Medical Care industry.

( Industry Median: 5.38 vs. HLS: 14.40 )
HLS' s 10-Year Net-margin (%) Range
Min: -36.52   Max: 48.3
Current: 14.4

-36.52
48.3
ROE (%) 93.91
HLS's ROE (%) is ranked higher than
100% of the 227 Companies
in the Global Medical Care industry.

( Industry Median: 9.51 vs. HLS: 93.91 )
HLS' s 10-Year ROE (%) Range
Min: -917.58   Max: 178.38
Current: 93.91

-917.58
178.38
ROA (%) 12.77
HLS's ROA (%) is ranked higher than
97% of the 234 Companies
in the Global Medical Care industry.

( Industry Median: 3.98 vs. HLS: 12.77 )
HLS' s 10-Year ROA (%) Range
Min: -18.6   Max: 37.9
Current: 12.77

-18.6
37.9
ROC (Joel Greenblatt) (%) 42.79
HLS's ROC (Joel Greenblatt) (%) is ranked higher than
86% of the 234 Companies
in the Global Medical Care industry.

( Industry Median: 17.97 vs. HLS: 42.79 )
HLS' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -8.85   Max: 61.32
Current: 42.79

-8.85
61.32
Revenue Growth (%) 8.70
HLS's Revenue Growth (%) is ranked higher than
77% of the 180 Companies
in the Global Medical Care industry.

( Industry Median: 7.20 vs. HLS: 8.70 )
HLS' s 10-Year Revenue Growth (%) Range
Min: -27   Max: 8.7
Current: 8.7

-27
8.7
EBITDA Growth (%) 17.30
HLS's EBITDA Growth (%) is ranked higher than
86% of the 161 Companies
in the Global Medical Care industry.

( Industry Median: 7.20 vs. HLS: 17.30 )
HLS' s 10-Year EBITDA Growth (%) Range
Min: 0   Max: 73.4
Current: 17.3

0
73.4
EPS Growth (%) -35.10
HLS's EPS Growth (%) is ranked higher than
54% of the 144 Companies
in the Global Medical Care industry.

( Industry Median: 9.30 vs. HLS: -35.10 )
HLS' s 10-Year EPS Growth (%) Range
Min: -36.3   Max: 67.3
Current: -35.1

-36.3
67.3
» HLS's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2013

HLS Guru Trades in Q1 2013

Jim Simons 406,100 sh (+74.29%)
Steven Cohen 36,299 sh (+22.84%)
Joel Greenblatt 200,904 sh (+17.85%)
Columbia Wanger 998,000 sh (+4.94%)
Vanguard Health Care Fund 386,000 sh (unchged)
Mariko Gordon 2,486,285 sh (unchged)
Chuck Royce 915,000 sh (unchged)
James Barrow 3,138,462 sh (-1.63%)
Tom Russo 3,500 sh (-20.45%)
» More
Q2 2013

HLS Guru Trades in Q2 2013

Paul Tudor Jones 7,300 sh (New)
Columbia Wanger 1,826,000 sh (+82.97%)
Mariko Gordon 2,539,114 sh (+2.12%)
Chuck Royce 915,000 sh (unchged)
Vanguard Health Care Fund 386,000 sh (unchged)
Stanley Druckenmiller Sold Out
Tom Russo Sold Out
James Barrow 3,077,747 sh (-1.93%)
Steven Cohen 27,661 sh (-23.8%)
Jim Simons 63,200 sh (-84.44%)
Joel Greenblatt 26,908 sh (-86.61%)
» More
Q3 2013

HLS Guru Trades in Q3 2013

Jim Simons 252,500 sh (+299.53%)
Columbia Wanger 3,281,000 sh (+79.68%)
Paul Tudor Jones Sold Out
Vanguard Health Care Fund Sold Out
Steven Cohen Sold Out
James Barrow 3,052,798 sh (-0.81%)
Mariko Gordon 2,399,098 sh (-5.51%)
Chuck Royce 773,500 sh (-15.46%)
Joel Greenblatt 12,717 sh (-52.74%)
» More
Q4 2013

HLS Guru Trades in Q4 2013

Vanguard Health Care Fund 24,624 sh (New)
Steven Cohen 34,975 sh (New)
Paul Tudor Jones 18,428 sh (New)
Jim Simons 581,500 sh (+130.3%)
Chuck Royce 773,500 sh (unchged)
Joel Greenblatt Sold Out
James Barrow 3,006,913 sh (-1.5%)
Mariko Gordon 2,334,292 sh (-2.7%)
Columbia Wanger 2,541,000 sh (-22.55%)
» More
» Details

Insider Trades

Latest Guru Trades with HLS

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Joel Greenblatt 2013-12-31 Sold Out 0.01%$33.2 - $36.48 $ 34.45-2%0
Vanguard Health Care Fund 2013-12-31 New Buy$33.2 - $36.48 $ 34.45-2%24624
Mariko Gordon 2013-09-30 Reduce -5.51%0.2%$29.01 - $34.54 $ 34.457%2399098
Vanguard Health Care Fund 2013-09-30 Sold Out 0.04%$29.01 - $34.54 $ 34.457%0
Joel Greenblatt 2013-09-30 Reduce -52.74%0.02%$29.01 - $34.54 $ 34.457%12717
Joel Greenblatt 2013-06-30 Reduce -86.61%0.23%$25.38 - $30.63 $ 34.4521%26908
Joel Greenblatt 2012-12-31 Add 210.51%0.14%$20.25 - $24.09 $ 34.4558%170476
Joel Greenblatt 2012-09-30 Reduce -22%0.03%$21.71 - $24.63 $ 34.4548%54902
Joel Greenblatt 2012-03-31 Add 101.22%0.07%$16.82 - $21.31 $ 34.4586%78962
George Soros 2011-12-31 Sold Out 0.06%$14.25 - $19.03 $ 34.45104%0
Joel Greenblatt 2011-12-31 Add 49.45%0.03%$14.25 - $19.03 $ 34.45104%39241
Joel Greenblatt 2011-09-30 Add 212.7%0.04%$14.81 - $26.88 $ 34.4564%26257
Vanguard Health Care Fund 2011-09-30 New Buy0.03%$14.81 - $26.88 $ 34.4564%386000
James Barrow 2011-09-30 Add 23.17%0.02%$14.81 - $26.88 $ 34.4564%2901992
George Soros 2011-09-30 Add 34.38%0.01%$14.81 - $26.88 $ 34.4564%214954
Joel Greenblatt 2011-06-30 New Buy0.03%$23.65 - $28.16 $ 34.4533%8397
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Preferred stocks of Healthsouth Corp

SymbolPriceYieldDescription
HSRPP1287.534.906 1/2% Conv Perp Pfd Shs Series -A-
HLSHP0.000.00Conv Pfd Shs Series A -144A

Ratios

vs
industry
vs
history
P/E(ttm) 14.20
HLS's P/E(ttm) is ranked higher than
90% of the 175 Companies
in the Global Medical Care industry.

( Industry Median: 21.80 vs. HLS: 14.20 )
HLS' s 10-Year P/E(ttm) Range
Min: 1.71   Max: 32.2
Current: 14.2

1.71
32.2
P/B 12.00
HLS's P/B is ranked lower than
74% of the 222 Companies
in the Global Medical Care industry.

( Industry Median: 2.29 vs. HLS: 12.00 )
HLS' s 10-Year P/B Range
Min: 8.08   Max: 191.71
Current: 12

8.08
191.71
P/S 1.57
HLS's P/S is ranked lower than
54% of the 232 Companies
in the Global Medical Care industry.

( Industry Median: 1.37 vs. HLS: 1.57 )
HLS' s 10-Year P/S Range
Min: 0.4   Max: 3.95
Current: 1.57

0.4
3.95
PFCF 13.90
HLS's PFCF is ranked higher than
73% of the 165 Companies
in the Global Medical Care industry.

( Industry Median: 15.52 vs. HLS: 13.90 )
HLS' s 10-Year PFCF Range
Min: 1.77   Max: 14.56
Current: 13.9

1.77
14.56
EV-to-EBIT 9.70
HLS's EV-to-EBIT is ranked higher than
91% of the 205 Companies
in the Global Medical Care industry.

( Industry Median: 17.82 vs. HLS: 9.70 )
HLS' s 10-Year EV-to-EBIT Range
Min: 5.8   Max: 86.1
Current: 9.7

5.8
86.1
PEG 0.90
HLS's PEG is ranked higher than
89% of the 105 Companies
in the Global Medical Care industry.

( Industry Median: 2.00 vs. HLS: 0.90 )
HLS' s 10-Year PEG Range
Min: 0.9   Max: 3.54
Current: 0.9

0.9
3.54
Shiller P/E 10.90
HLS's Shiller P/E is ranked higher than
94% of the 105 Companies
in the Global Medical Care industry.

( Industry Median: 24.97 vs. HLS: 10.90 )
HLS' s 10-Year Shiller P/E Range
Min: 5.21   Max: 875
Current: 10.9

5.21
875

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 1.57
HLS's Dividend Yield is ranked lower than
53% of the 139 Companies
in the Global Medical Care industry.

( Industry Median: 1.70 vs. HLS: 1.57 )
HLS' s 10-Year Dividend Yield Range
Min: 0.5   Max: 1.16
Current: 1.57

0.5
1.16
Dividend Payout 0.16
HLS's Dividend Payout is ranked higher than
85% of the 108 Companies
in the Global Medical Care industry.

( Industry Median: 0.36 vs. HLS: 0.16 )
HLS' s 10-Year Dividend Payout Range
Min: 0.14   Max: 0.14
Current: 0.16

Yield on cost (5-Year) 1.60
HLS's Yield on cost (5-Year) is ranked lower than
59% of the 144 Companies
in the Global Medical Care industry.

( Industry Median: 2.09 vs. HLS: 1.60 )
HLS' s 10-Year Yield on cost (5-Year) Range
Min: 0.5   Max: 1.16
Current: 1.6

0.5
1.16
Share Buyback Rate 2.00
HLS's Share Buyback Rate is ranked higher than
91% of the 163 Companies
in the Global Medical Care industry.

( Industry Median: -1.40 vs. HLS: 2.00 )
HLS' s 10-Year Share Buyback Rate Range
Min: 2.6   Max: -34.1
Current: 2

Valuation & Return

vs
industry
vs
history
Price/DCF (Projected) 1.20
HLS's Price/DCF (Projected) is ranked higher than
56% of the 122 Companies
in the Global Medical Care industry.

( Industry Median: 1.10 vs. HLS: 1.20 )
HLS' s 10-Year Price/DCF (Projected) Range
Min: 0.87   Max: 209.14
Current: 1.2

0.87
209.14
Price/Median PS Value 1.40
HLS's Price/Median PS Value is ranked lower than
63% of the 206 Companies
in the Global Medical Care industry.

( Industry Median: 1.10 vs. HLS: 1.40 )
HLS' s 10-Year Price/Median PS Value Range
Min: 0.44   Max: 2.74
Current: 1.4

0.44
2.74
Price/Peter Lynch Fair Value 1.50
HLS's Price/Peter Lynch Fair Value is ranked higher than
55% of the 58 Companies
in the Global Medical Care industry.

( Industry Median: 1.50 vs. HLS: 1.50 )
HLS' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.48   Max: 2.13
Current: 1.5

0.48
2.13
Earnings Yield (Greenblatt) 10.30
HLS's Earnings Yield (Greenblatt) is ranked higher than
90% of the 221 Companies
in the Global Medical Care industry.

( Industry Median: 5.50 vs. HLS: 10.30 )
HLS' s 10-Year Earnings Yield (Greenblatt) Range
Min: 1.2   Max: 17.1
Current: 10.3

1.2
17.1
Forward Rate of Return (Yacktman) 16.26
HLS's Forward Rate of Return (Yacktman) is ranked higher than
83% of the 169 Companies
in the Global Medical Care industry.

( Industry Median: 11.19 vs. HLS: 16.26 )
HLS' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -48.8   Max: 18.4
Current: 16.26

-48.8
18.4

Business Description

Industry: Health Care Providers » Medical Care
Compare:CHE, DVA, FSNUY, BDUUF, SKHCY » details
Traded in other countries:HSRPP.USA, HSOA.Germany
HealthSouth Corp is a provider of inpatient rehabilitative health care services in the United States. HealthSouth Corp was organized as a Delaware corporation in February 1984. The Company is a provider of inpatient rehabilitative healthcare services. The Company's inpatient rehabilitation hospitals offer specialized rehabilitative care across an array of diagnoses and deliver patient care services. Patient care is provided by nursing and therapy staff as directed by a physician order. As of December 31, 2011, it operated 99 inpatient rehabilitation hospitals (including 3 hospitals that operate as joint ventures which it account for using the equity method of accounting), 26 outpatient rehabilitation satellite clinics (operated by its hospitals, including one joint venture satellite), and 25 licensed, hospital-based home health agencies. In addition to HealthSouth hospitals, it manages three inpatient rehabilitation units through management contracts. While it's national network of inpatient hospitals stretches across 27 states and Puerto Rico, its inpatient hospitals are concentrated in the eastern half of the United States and Texas. The Company's inpatient rehabilitation hospitals compete with rehabilitation units, many of which are within acute care hospitals, and skilled nursing facilities in the market. It treat patients of all ages, its patients are persons 65 and older. The company is subject to significant federal, state, and local regulation that affects business activities by controlling the reimbursement received for services provided, requiring licensure or certification of hospitals, regulating of relationships with physicians and other referral sources, regulating the use of its properties, and controlling its growth.

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Hide